GlassScriptPhysician profile
Parivash Mohamadi
NPI 1295791853
$6,041.09
in general payments reported to CMS, 2019-2025
28 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $564 · 2021: $2,295 · 2022: $982 · 2023: $852 · 2024: $556 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,488.95 | 2021 | |
| Abbvie INC. | $1,172.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $886.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Allergan, INC. | $651.96 | 2019-2020 | |
| Lilly USA, LLC | $249.63 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $197.16 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $172.46 | 2020-2022 | |
| Novo Nordisk INC | $169.16 | 2022-2023 | Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.05 | 2020-2023 | Jardiance |
| Glaxosmithkline, LLC. | $105.41 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.38 | 2021-2024 | Xifaxan |
| Almatica Pharma LLC | $97.62 | 2021-2022 | |
| Celgene Corporation | $83.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $82.77 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $68.47 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.87 | 2024 | Tepezza, Otezla, Repatha |
| Lundbeck LLC | $41.75 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $35.52 | 2020-2021 | |
| Janssen Biotech, INC. | $28.87 | 2019 | |
| Exact Sciences Corporation | $27.58 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $24.84 | 2022 | |
| Vertical Pharmaceuticals, LLC | $22.42 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.16 | 2022 | |
| Averitas Pharma INC. | $21.01 | 2025 | Qutenza |
| Abbott Laboratories | $20.62 | 2024 | Eterna |
| Sanofi-Aventis U.S. LLC | $19.33 | 2021 | |
| Horizon Therapeutics Plc | $16.56 | 2019 | |
| Currax Pharmaceuticals LLC | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parivash Mohamadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.